Clinical Trial Update: Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation [Phase 1]

View source ↗

Summary

Phase 1 single-dose crossover study compared the bioavailability of eslicarbazepine acetate to a to-be-marketed formulation in epilepsy; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• eslicarbazepine acetate (eslicarbazepine acetate)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2014-12-10